A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals Corporation
- 10 Aug 2016 Status changed from not yet recruiting to recruiting.
- 10 Aug 2016 Planned End Date changed from 1 Feb 2017 to 1 Sep 2017.
- 10 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2017.